Pharming Group (NASDAQ:PHAR) Stock Bumped Up to “Strong-Buy” by Wall Street Zen

Wall Street Zen upgraded shares of Pharming Group (NASDAQ:PHAR) from a hold rating to a strong-buy rating in a report issued on Sunday,Wall Street Zen reports.

Other research analysts also recently issued research reports about the company. Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a report on Wednesday. Canaccord Genuity Group increased their price target on Pharming Group from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, September 22nd. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, October 23rd. Finally, Weiss Ratings upgraded shares of Pharming Group from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, October 27th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $39.67.

Pharming Group Price Performance

PHAR stock opened at $12.23 on Friday. The company has a current ratio of 3.23, a quick ratio of 2.65 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $865.64 million, a P/E ratio of 38.22 and a beta of -0.05. The business has a 50 day simple moving average of $10.71 and a 200-day simple moving average of $13.80. Pharming Group has a twelve month low of $9.11 and a twelve month high of $21.34.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. The company had revenue of $117.60 million for the quarter, compared to analysts’ expectations of $117.60 million. Pharming Group had a return on equity of 8.70% and a net margin of 6.23%. As a group, equities analysts anticipate that Pharming Group will post 0.34 EPS for the current year.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.